Terremoto Biosciences: $108 Million Series C Raised To Advance AKT1-Selective Oncology And Rare Disease Programs
By Amit Chowdhry ● Apr 18, 2026
Terremoto Biosciences, a clinical-stage biotechnology company focused on highly selective small molecule therapies, announced it has closed a $108 million Series C financing to advance its pipeline targeting cancer and rare diseases. The round included new investors RA Capital Management, Deep Track Capital, Osage University Partners, and BeOne Medicines, alongside existing backers OrbiMed, Third Rock Ventures, Novo Holdings, and Cormorant Asset Management.